Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Trader Gu Jingci: November 9 Bitcoin/Ethereum Trading Strategy and Market Analysis

Trader Gu Jingci: November 9 Bitcoin/Ethereum Trading Strategy and Market Analysis

AiCoinAiCoin2026/11/09 05:35
Show original

Follow and stay updated for substantial gains. Hello everyone, I am analyst Gu Jingci. I share my insights here in hopes that every follower achieves a good return!

Bitcoin/Ethereum experienced another significant drop towards the end of the weekly candle close, with the weekly trend fully deteriorating. The current lows will not serve as the bottom, and there is still room for further decline in the following trend. However, the most recent four-hour chart shows a massive bearish candlestick with a long lower shadow, indicating some buying support during the decline, though the overall downward momentum remains strong. From a technical perspective, on the four-hour chart, both the DIF and DEA lines of the MACD indicator are running below the zero axis, and the DIF line continues to cross below the DEA line. The MACD histogram is negative and expanding, suggesting that bearish forces are dominant and the downward trend remains intact. In the short term, after a rapid descent, the market still has room for a rebound and correction. The upper ranges of 76,000 to 76,500 for Bitcoin and 2,200 to 2,240 for Ethereum—which acted as sideways trading zones over the weekend—now pose new resistance for this round of trend reversal.

Trading suggestion: Go long on Bitcoin near 74,000 to 74,500, with a target around 75,800; go long on Ethereum near 2,110 to 2,130, with a target around 2,180; stop losses at 73,000 and 2,080, respectively.

We are here every day, not to prove how high our win rate is, but to let you know that our team is always present, monitoring the market around the clock with professionalism and reliability. All analysis and strategies are for reference only; bear your own risks. Articles are reviewed and published without real-time accuracy, so always refer to real-time data for specifics!

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12